Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

Investigational New Drugs

Volumn 22, Issue 3, 2004, Pages 329-333

  De Jonge, M J A ^a   Droz, J P ^b   Paz Ares, L ^c   Van Oosterom, A T ^d   De Wit, R ^a   Chollet, P ^e   Baron, B ^f   Lacombe, D ^f   Mettinger, K ^h   Fumoleau, P ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRE LÉON BÉRARD   (France)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e CENTRE JEAN PERRIN   (France)

^f EORTC DATA CENTER   (Belgium)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h SuperGen Inc   (United States)

Author keywords

9 nitrocamptothecin; Oral chemotherapy; Topoisomerase I inhibitors; Urothelial tract tumors

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GELATIN; GEMCITABINE; RUBITECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTITIS; DIARRHEA; DRUG CAPSULE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID INTAKE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR VOLUME; UROGENITAL TRACT TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 3543039988     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000026260.24275.02     Document Type: Article

References (21)

1. Parker DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999
2. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985
3. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR: MVAC (methotrexate, vinblastine, doxorubicin and cisplatinum) for advanced transitional cell carcinoma of the urothelium. J Urol 139(3): 461-469, 1988
4. Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, Van Oosterom AT, Witjes F, Spina M, Van Groeningen CJ, De Balincourt C, Collette L: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19(10):2638-2646, 2001
5. Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncology 10: 1066-1073, 1992
6. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus methotreaxte, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17: 3068-3077, 2000
7. Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G: Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of the bladder. Invest New Drugs 15(2): 157-163, 1997
8. Papamichael D, Gallagher CJ, Oliver RTD, Johnson PW, Waxman J: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75: 606-607, 1997
9. Vaughn DJ, Broome CM, Hussain M, Gutheil J, Markowitz AB: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(4): 937-940, 2002
10. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853-1857, 1997
11. Manola JB, Dreicer R, Wilding G: Abstract: Gemcitabine and docetaxel in advanced carcinoma of the urothelium: Report of a phase II Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 21;200a, 2002
12. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Giovanella BC: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5(8): 273-281, 1993
13. Giovanella BC, Stehlin JS, Hinz HR, Vardeman D, Mendoza JT, Potmesil M: Abstract: Studies on time/dose intensity in treatment of human cancer xenografts with camptothecin analogues. Proc Am Assoc Cancer Res 35: 455, 1994
14. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, Giovanella BC: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980-3987, 1992
15. Supko JG, Malspeis L: Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 53: 3062-3069, 1993
16. Supko JG, Plowman J, Dykes DJ, Zaharko DS: Abstract: Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33: 432, 1992
17. Gerrits CJH, de Jonge MJA, Schellens JHM, Stoter G, Verweij J: Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 76: 952-962, 1997
18. Verschaegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase inhibitor. Anticancer Drugs 9: 36-44, 1998
19. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, Stathopoulos GP, Manouras AP, Mylonaki DB, Golematis BX: A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48: 417-420, 2001
20. Raymond E, Campone M, Stupp R, Menten J, Chollet P, Lesimple T, Fety-Deoporte R, Lacombe D, Paoletti X, Fumoleau P: EORTC Early Clinical Studies Group (ECSG); Brain Tumor Studies Group (BTSG) New Drug Development Program (NDDP): Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 38: 1348-1350, 2002
21. Schöffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, Volk J, Ganser A, Adank S, Botma HJ, Wanders J: Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 38: 807-813, 2002